SCHEDULE: Nantahala Capital Boosts Opus Genetics Stake to 9.99%

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Opus Genetics, Inc., including shares acquirable via warrants.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") collectively reported beneficial ownership of 7,123,506 shares of Opus Genetics, Inc. common stock.
• This ownership represents 9.99% of the total class of securities outstanding as of December 31, 2025.
• The reported shares include 2,342,176 shares that can be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• Nantahala Capital Management, LLC is classified as an investment adviser, while Wilmot B. Harkey and Daniel Mack are classified as control persons.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, holds the right to receive dividends or proceeds from more than five percent of the beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Opus Genetics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a prominent investment adviser and its control persons have maintained a substantial stake, including potential future ownership through warrants, in Opus Genetics, Inc.

Positives

• A significant institutional investor, Nantahala Capital Management, LLC, maintains a substantial 9.99% stake in Opus Genetics, Inc., indicating continued confidence.
• The inclusion of 2,342,176 shares acquirable through warrants suggests potential for increased ownership and long-term interest from the reporting persons.

Future Outlook

NA

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake by an investment adviser like Nantahala Capital Management, known for its focus on healthcare and biotechnology, can signal institutional confidence in Opus Genetics, Inc.'s long-term prospects within the specialized genetics sector. Such disclosures are closely watched by the market as they can influence investor perception and potentially attract further institutional interest, especially for a company in the genetics space where R&D and clinical milestones are critical.

Related Party Transactions

• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala Capital Management, LLC, has the right to receive or direct dividends and proceeds from the sale of more than five percent of the outstanding shares beneficially owned by Nantahala.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence and potentially attract other investors, positively impacting share price.
• Company Management: A large institutional holder can exert influence on strategic decisions, though the filing states the stake is not for control purposes.

Key Dates

Recommendation

While the significant institutional stake by Nantahala Capital Management, including warrants, suggests confidence from a sophisticated investor, this Schedule 13G filing primarily provides ownership information rather than operational or financial performance updates. Without additional context on Opus Genetics' recent performance, strategic developments, or valuation, a 'hold' recommendation is prudent. The filing indicates a stable, substantial institutional presence, which is generally a positive indicator, but does not provide new catalysts for a 'buy' or 'sell' decision.

Keywords

Opus Genetics, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, beneficial ownership, Schedule 13G, common stock, institutional investment, warrants, equity stake